ArticleInfection and immunity2000
Prophylactic and therapeutic efficacy of antibodies to a capsular polysaccharide shared among vancomycin-sensitive and -resistant enterococci.
Article in Infection and immunity, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 83 citations in OpenAlex.
- Novel recombinant VH43 antibody fragment potentiates the antibacterial activity of cephalosporins against Enterococcus faecium.Archives of microbiology · 2026Article
- A rabbit model of acute bacteremia and sepsis caused by vancomycin-resistantFrontiers in cellular and infection microbiology · 2026Article
- Insights into ecology, pathogenesis, and biofilm formation ofMicrobiology and molecular biology reviews : MMBR · 2025Review
- Enterococcus faecium: evolution, adaptation, pathogenesis and emerging therapeutics.Nature reviews. Microbiology · 2024Review
- Promiscuous, persistent and problematic: insights into current enterococcal genomics to guide therapeutic strategy.BMC microbiology · 2024Review
- Streptococcus pneumoniae, S. mitis, and S. oralis Produce a Phosphatidylglycerol-Dependent,mSphere · 2021Article
- Generation of glucosylatedRSC chemical biology · 2021Article
- Review
- Conjugation of Different Immunogenic Enterococcal Vaccine Target Antigens Leads to Extended Strain Coverage.The Journal of infectious diseases · 2019Article
- Pathogenicity of Enterococci.Microbiology spectrum · 2019Review
- Potential targets for next generation antimicrobial glycoconjugate vaccines.FEMS microbiology reviews · 2018Review
- Streamlined Synthesis and Evaluation of Teichoic Acid Fragments.Chemistry (Weinheim an der Bergstrasse, Germany) · 2018Article
- A Vaccine Approach for the Prevention of Infections by Multidrug-resistant Enterococcus faecium.The Journal of biological chemistry · 2015Article
- Characterization of Two Metal Binding Lipoproteins as Vaccine Candidates for Enterococcal Infections.PloS one · 2015Article
- Isolation of highly active monoclonal antibodies against multiresistant gram-positive bacteria.PloS one · 2015Article
- Detection of opsonic antibodies against Enterococcus faecalis cell wall carbohydrates in immune globulin preparations.Infection · 2014Article
- Targeting pili in enterococcal pathogenesis.Infection and immunity · 2014Article
- Cell-wall glycolipid mutations and their effects on virulence of E. faecalis in a rat model of infective endocarditis.PloS one · 2014Article
- Article
- Identification of peptidoglycan-associated proteins as vaccine candidates for enterococcal infections.PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Enterococci are important nosocomial pathogens that are increasingly difficult to treat due to intrinsic and acquired resistance to antibiotics, including vancomycin. A recently described capsular polysaccharide (CP) isolated from Enterococcus faecalis 12030 was used to evaluate the potential efficacy of active or passive immunotherapy regimens as adjunctive treatments. Evaluation of protective efficacy was carried out in immunocompetent mice challenged intravenously (i.v.) with live enterococci. In nonimmune mice, i.v. inoculations resulted in high levels of bacteria in kidneys, spleens, and livers 5 days after challenge. Mice immunized with four 10-microg doses of CP antigen/mouse were protected against challenge with the homologous E. faecalis strain. High-titer opsonic immunoglobulin G was also induced by immunizing rabbits with the purified CP, and passive transfer of this antiserum to mice produced significantly lower bacterial counts in organs than did normal rabbit serum or sterile saline. Antibodies to the polysaccharide isolated from E. faecalis 12030 were protective against Enterococcus faecalis OG1RF and against two serologically related, vancomycin-resistant Enterococcus faecium clinical isolates. Antibodies to this CP antigen were also effective as a therapeutic reagent in mice when passive therapy was initiated 48 h after live bacterial challenge. These data indicate that CP antigens from enterococci are potential targets of protective antibodies and that these antibodies may be useful for prophylaxis and treatment of enterococcal infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.